Links for fulltext
(May Require Subscription)
- Publisher Website: 10.1080/2162402X.2015.1115178
- Scopus: eid_2-s2.0-84962886163
- PMID: 27141397
- WOS: WOS:000374194200028
- Find via
Supplementary
- Citations:
- Appears in Collections:
Article: Advances in clinical NK cell studies: Donor selection, manufacturing and quality control
Title | Advances in clinical NK cell studies: Donor selection, manufacturing and quality control |
---|---|
Authors | |
Keywords | ex vivo expansion quality control manufacturing of NK cell products Clinical NK cell studies |
Issue Date | 2016 |
Citation | OncoImmunology, 2016, v. 5, n. 4, article no. e1115178 How to Cite? |
Abstract | Natural killer (NK) cells are increasingly used in clinical studies in order to treat patients with various malignancies. The following review summarizes platform lectures and 2013–2015 consortium meetings on manufacturing and clinical use of NK cells in Europe and United States. A broad overview of recent pre-clinical and clinical results in NK cell therapies is provided based on unstimulated, cytokine-activated, as well as genetically engineered NK cells using chimeric antigen receptors (CAR). Differences in donor selection, manufacturing and quality control of NK cells for cancer immunotherapies are described and basic recommendations are outlined for harmonization in future NK cell studies. |
Persistent Identifier | http://hdl.handle.net/10722/294515 |
ISSN | 2014 Impact Factor: 6.266 2023 SCImago Journal Rankings: 2.345 |
PubMed Central ID | |
ISI Accession Number ID |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Koehl, U. | - |
dc.contributor.author | Kalberer, C. | - |
dc.contributor.author | Spanholtz, J. | - |
dc.contributor.author | Lee, D. A. | - |
dc.contributor.author | Miller, J. S. | - |
dc.contributor.author | Cooley, S. | - |
dc.contributor.author | Lowdell, M. | - |
dc.contributor.author | Uharek, L. | - |
dc.contributor.author | Klingemann, H. | - |
dc.contributor.author | Curti, A. | - |
dc.contributor.author | Leung, W. | - |
dc.contributor.author | Alici, E. | - |
dc.date.accessioned | 2020-12-03T08:22:54Z | - |
dc.date.available | 2020-12-03T08:22:54Z | - |
dc.date.issued | 2016 | - |
dc.identifier.citation | OncoImmunology, 2016, v. 5, n. 4, article no. e1115178 | - |
dc.identifier.issn | 2162-4011 | - |
dc.identifier.uri | http://hdl.handle.net/10722/294515 | - |
dc.description.abstract | Natural killer (NK) cells are increasingly used in clinical studies in order to treat patients with various malignancies. The following review summarizes platform lectures and 2013–2015 consortium meetings on manufacturing and clinical use of NK cells in Europe and United States. A broad overview of recent pre-clinical and clinical results in NK cell therapies is provided based on unstimulated, cytokine-activated, as well as genetically engineered NK cells using chimeric antigen receptors (CAR). Differences in donor selection, manufacturing and quality control of NK cells for cancer immunotherapies are described and basic recommendations are outlined for harmonization in future NK cell studies. | - |
dc.language | eng | - |
dc.relation.ispartof | OncoImmunology | - |
dc.rights | This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. | - |
dc.subject | ex vivo expansion | - |
dc.subject | quality control | - |
dc.subject | manufacturing of NK cell products | - |
dc.subject | Clinical NK cell studies | - |
dc.title | Advances in clinical NK cell studies: Donor selection, manufacturing and quality control | - |
dc.type | Article | - |
dc.description.nature | published_or_final_version | - |
dc.identifier.doi | 10.1080/2162402X.2015.1115178 | - |
dc.identifier.pmid | 27141397 | - |
dc.identifier.pmcid | PMC4839369 | - |
dc.identifier.scopus | eid_2-s2.0-84962886163 | - |
dc.identifier.volume | 5 | - |
dc.identifier.issue | 4 | - |
dc.identifier.spage | article no. e1115178 | - |
dc.identifier.epage | article no. e1115178 | - |
dc.identifier.eissn | 2162-402X | - |
dc.identifier.isi | WOS:000374194200028 | - |
dc.identifier.issnl | 2162-4011 | - |